Phase II Study of High-Dose Somatostatin Analogue in Patients Either Previously Treated or Untreated Who Have Extensive-Stage Small Cell Lung Cancer
| Autor: | Robert F. Marschke, James B. Gerstner, Donald B. Wender, James A. Mailliard, Roscoe F. Morton, Chirantan Ghosh, James R. Jett, Ralph Levitt, Joseph P. Grill, Jeff A. Sloan |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Lung Neoplasms Antineoplastic Agents Hormonal medicine.medical_treatment Phases of clinical research Anorexia Small-cell carcinoma Gastroenterology Internal medicine medicine Humans Carcinoma Small Cell Survival analysis Aged Neoplasm Staging Chemotherapy business.industry Respiratory disease Middle Aged medicine.disease Survival Analysis Surgery Somatostatin Oncology Toxicity Female medicine.symptom business |
| Zdroj: | American Journal of Clinical Oncology. 22:15-17 |
| ISSN: | 0277-3732 |
| DOI: | 10.1097/00000421-199902000-00004 |
| Popis: | The authors conducted a phase II study of somatostatin analogue in 18 patients with extensive stage small cell lung cancer (four with previous treatment, 14 without previous treatment). Patients received 2,000 mg subcutaneously thrice daily. They were required to have an Eastern Cooperative Oncology Group performance score of 0-2 and acceptable pretreatment biochemical parameters. No patient responded to treatment. The median time to progression was 44 days. The median survival was 106 days. Toxicity related to treatment consisted of mild diarrhea and anorexia. Somatostatin analogue is not active as a single agent in the treatment of extensive-stage small cell lung cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|